| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
101,390,000 |
| Market
Cap: |
2.04(B) |
| Last
Volume: |
668,805 |
Avg
Vol: |
663,419 |
| 52
Week Range: |
$16.33 - $21.8 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Innoviva is a company with a portfolio of royalties and other healthcare assets. Co.'s royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and TRELEGY® ELLIPTA®. Co. is entitled to royalty payments made by GSK under its agreements that assigned to Theravance Respiratory Company, LLC (TRC), including TRELEGY® ELLIPTA® and any other product or combination of products that may be discovered or developed in the future under the Long-Acting Beta2 Agonist Collaboration Agreement and the Strategic Alliance Agreement with GSK, which have been assigned to TRC other than RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
1,618,295 |
1,618,295 |
1,629,289 |
| Total Sell Value |
$0 |
$28,395,442 |
$28,395,442 |
$28,549,252 |
| Total People Sold |
0 |
1 |
1 |
2 |
| Total Sell Transactions |
0 |
3 |
3 |
4 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Zhen Marianne |
Chief Accounting Officer |
• – – |
2025-05-20 |
4 |
D |
$18.78 |
$18,630 |
D/D |
(992) |
50,320 |
|
- |
|
| Basso Stephen |
Chief Financial Officer |
• – – |
2025-05-20 |
4 |
D |
$18.78 |
$4,451 |
D/D |
(237) |
23,518 |
|
- |
|
| Small Derek A |
Director |
– • – |
2025-05-19 |
4 |
A |
$0.00 |
$0 |
D/D |
12,077 |
35,249 |
|
- |
|
| Schlesinger Sarah J. |
Director |
– • – |
2025-05-19 |
4 |
A |
$0.00 |
$0 |
D/D |
12,077 |
130,706 |
|
- |
|
| Dipaolo Mark |
Director |
– • – |
2025-05-19 |
4 |
A |
$0.00 |
$0 |
D/D |
12,077 |
130,706 |
|
- |
|
| Haimovitz Jules |
Director |
– • – |
2025-05-19 |
4 |
A |
$0.00 |
$0 |
D/D |
12,077 |
142,906 |
|
- |
|
| Basso Stephen |
Chief Financial Officer |
• – – |
2025-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
1,353 |
23,755 |
|
- |
|
| Sarissa Capital Management Lp |
|
• • • |
2025-03-06 |
4 |
S |
$17.52 |
$20,964,237 |
I/I |
(1,196,746) |
5,658,705 |
|
-13% |
|
| Sarissa Capital Management Lp |
|
• • • |
2025-03-05 |
4 |
S |
$17.63 |
$4,766,126 |
I/I |
(270,374) |
6,855,451 |
|
-13% |
|
| Sarissa Capital Management Lp |
|
• • • |
2025-03-04 |
4 |
S |
$17.63 |
$2,665,079 |
I/I |
(151,175) |
7,125,825 |
|
-14% |
|
| Zhen Marianne |
Chief Accounting Officer |
• • – |
2025-02-20 |
4 |
D |
$18.07 |
$46,350 |
D/D |
(2,565) |
42,374 |
|
- |
|
| Basso Stephen |
Chief Financial Officer |
• • – |
2025-02-20 |
4 |
D |
$18.07 |
$19,985 |
D/D |
(1,106) |
11,833 |
|
- |
|
| Zhen Marianne |
Chief Accounting Officer |
• – – |
2024-11-20 |
4 |
D |
$19.15 |
$18,690 |
D/D |
(976) |
44,939 |
|
- |
|
| Basso Stephen |
Chief Financial Officer |
• • – |
2024-11-15 |
4 |
A |
$0.00 |
$0 |
D/D |
843 |
12,939 |
|
- |
|
| Zhen Marianne |
Chief Accounting Officer |
• – – |
2024-11-15 |
4 |
A |
$0.00 |
$0 |
D/D |
300 |
45,915 |
|
- |
|
| Zhen Marianne |
Chief Accounting Officer |
• – – |
2024-08-20 |
4 |
D |
$18.49 |
$18,028 |
D/D |
(975) |
45,615 |
|
- |
|
| Dipaolo Mark |
Director |
– • – |
2024-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
13,923 |
118,629 |
|
- |
|
| Srivastava Sapna |
Director |
– • – |
2024-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
13,923 |
44,096 |
|
- |
|
| Small Derek A |
Director |
– • – |
2024-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
13,923 |
23,172 |
|
- |
|
| Kostas Odysseas D |
Director |
– • – |
2024-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
13,923 |
122,625 |
|
- |
|
| Schlesinger Sarah J. |
Director |
– • – |
2024-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
13,923 |
118,629 |
|
- |
|
| Haimovitz Jules |
Director |
– • – |
2024-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
13,923 |
130,829 |
|
- |
|
| Ronsheim Matthew |
See Remarks |
• • – |
2024-05-20 |
4 |
D |
$16.13 |
$4,323 |
D/D |
(268) |
40,510 |
|
- |
|
| Zhen Marianne |
Chief Accounting Officer |
• • – |
2024-05-20 |
4 |
D |
$16.13 |
$15,743 |
D/D |
(976) |
46,590 |
|
- |
|
| Zhen Marianne |
Chief Accounting Officer |
• – – |
2024-03-05 |
4 |
A |
$14.88 |
$159,990 |
D/D |
10,752 |
47,566 |
|
- |
|
227 Records found
|
|
Page 1 of 10 |
|
|
0.13 (0.65%) 
